A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2019Cited by 27
First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.Nehal J. Lakhani, Yifan Zhai, Drew Rasco et al.|Journal of Clinical Oncology|2020Cited by 20
A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.Xing Zhang, Yifan Zhai, Xizhi Wen et al.|Journal of Clinical Oncology|2019Cited by 8
Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to VenetoclaxMatthew S. Davids, Yifan Zhai, Sikander Ailawadhi et al.|Blood|2024Cited by 8
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.Xing Zhang, Yifan Zhai, Xizhi Wen et al.|Journal of Clinical Oncology|2020Cited by 7